In 1945, philanthropist Alfred P. Sloan, Jr., and engineer Charles F. Kettering founded the Sloan Kettering Institute (SKI) on New York City’s Upper East Side, with the vision of harnessing the latest research techniques in order to conquer cancer. This goal endures today.
As the experimental research arm of Memorial Sloan Kettering Cancer Center, SKI is focused on the pursuit of fundamental scientific discoveries. The institute’s philosophy is that the best way to fuel progress in cancer treatment is to support scientists as they explore the unknown.
SKI is distinguished by its:
SKI exists as a distinct entity within the larger community of scholars, clinicians, and researchers that make up MSK. SKI hosts more than 100 laboratory investigators, 400 postdoctoral research fellows (including clinical fellows), and 300 PhD and MD/PhD graduate students. The institute enjoys a close relationship with neighbors Weill Cornell Medicine and The Rockefeller University.
Over the course of its 70-year history, SKI has produced many advances in our understanding of biology and medicine. SKI scientists have discovered cancer-related genes, unraveled signaling pathways that control cell growth and division, and identified the cell types involved in mounting and repressing immune responses. SKI research has also been a driver of clinical advances in cancer treatment, from chemotherapy to targeted therapy to immunotherapy.
SKI scientists are leaders in their fields. Many are members of the National Academies of Science and Medicine. Many are Howard Hughes Medical Institute investigators and the recipients of many awards and honors.